PAH drug study halted: LTP001 fails to show promise
NCT ID NCT05135000
First seen Jan 14, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. The goal was to see if the drug could improve blood flow and exercise ability. The study was stopped early, and results were not strong enough to continue development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical Univ of South Carolina
Charleston, South Carolina, 29425, United States
-
Novartis Investigative Site
Caba, Buenos Aires, C1025ABI, Argentina
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Amsterdam, 1081 HV, Netherlands
-
Novartis Investigative Site
Krakow, 31 202, Poland
-
Novartis Investigative Site
Lodz, 91-347, Poland
-
Novartis Investigative Site
Wroclaw, 50-556, Poland
-
Novartis Investigative Site
Málaga, Andalusia, 29010, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Novartis Investigative Site
London, SW3 6PH, United Kingdom
-
Pulmonary Associates PA
Mesa, Arizona, 85206, United States
Conditions
Explore the condition pages connected to this study.